Seroatlas · Human Serome Atlas

EGFL7

Epidermal growth factor-like protein 7

Also known as: EGFL7_HUMAN, ZNEU1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UHF1
Gene: EGFL7
Ensembl: ENSG00000172889
Chromosome: 9
Canonical length: 273 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted to extracellular matrix

OverviewNCBI Gene

This gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]

Canonical amino-acid sequenceUniProt

273 residues, UniProt reviewed canonical sequence.

>Q9UHF1|EGFL7
     1  MRGSQEVLLM WLLVLAVGGT EHAYRPGRRV CAVRAHGDPV SESFVQRVYQ PFLTTCDGHR
    61  ACSTYRTIYR TAYRRSPGLA PARPRYACCP GWKRTSGLPG ACGAAICQPP CRNGGSCVQP
   121  GRCRCPAGWR GDTCQSDVDE CSARRGGCPQ RCVNTAGSYW CQCWEGHSLS ADGTLCVPKG
   181  GPPRVAPNPT GVDSAMKEEV QRLQSRVDLL EEKLQLVLAP LHSLASQALE HGLPDPGSLL
   241  VHSFQQLGRI DSLSEQISFL EEQLGSCSCK KDS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EGFL7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.47
Highest tissue expression: 243 nTPM

Expression across tissuesHPA

Tissue

heart muscle: 243 nTPM
lung: 199 nTPM
adipose tissue: 190 nTPM
breast: 189 nTPM
spleen: 186 nTPM
placenta: 171 nTPM

Single-cell type

hofbauer cells: 666 nCPM
vascular endothelial cells: 574 nCPM
platelets: 382 nCPM
lymphatic endothelial cells: 381 nCPM
epididymal principal cells: 237 nCPM
differentiating spermatogonia: 192 nCPM

Immune cell

intermediate monocyte: 6.2 nTPM
plasmacytoid DC: 5.9 nTPM
non-classical monocyte: 5.6 nTPM
eosinophil: 3.5 nTPM
total PBMC: 2.4 nTPM
classical monocyte: 2.1 nTPM

Brain region

thalamus: 114 nTPM
amygdala: 106 nTPM
cerebral cortex: 99 nTPM
medulla oblongata: 90 nTPM
pons: 88 nTPM
midbrain: 82 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.92
gnomAD pLI: 0
gnomAD missense Z: -0.32
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EGFL7 as an antibody target. Whether an autoantibody or antibody against EGFL7 could matter depends on whether native EGFL7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EGFL7 is annotated as secreted, so native EGFL7 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label EGFL7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...